What is Arrayus?
Arrayus Technologies Inc. is at the forefront of oncological care innovation, developing a non-invasive focused ultrasound therapy platform designed to revolutionize cancer treatment. This advanced technology offers a safer, more efficient alternative to traditional surgery, functioning as an outpatient option that complements existing therapies such as chemotherapy and radiation. Leveraging sophisticated MRI image guidance and real-time monitoring, Arrayus provides versatile treatment solutions for patients with previously inoperable conditions. The company's strategic research and collaboration efforts are spearheaded by Dr. Kullervo Hynynen, a recognized pioneer in the field of focused ultrasound.
How much funding has Arrayus raised?
Arrayus has raised a total of $1.9M across 1 funding round:
Grant
$1.9M
Grant (2023): $1.9M with participation from Government of Canada
Key Investors in Arrayus
Government of Canada
The Government of Canada, through its official digital portal Canada.ca, provides comprehensive public services and resources. This federal entity, established in 1867, supports various sectors including healthcare and research, reflecting a commitment to advancing public welfare and innovation.
What's next for Arrayus?
The recent major strategic investment signals a pivotal phase for Arrayus, likely enabling the company to accelerate its product development, scale manufacturing capabilities, and expand its market reach. This enterprise-level funding will be instrumental in navigating regulatory pathways and initiating clinical trials, positioning Arrayus to make a substantial impact on oncological care. The company's focus on non-invasive therapeutic solutions aligns with a growing demand for less burdensome and more effective cancer treatments.
See full Arrayus company page
